Natera (NTRA) Insider Roy Baynes Buys 1,646 Shares
Roy Baynes bought 1,646 shares of Natera, Inc. on June 26, 2026, as insiders showed strong interest in the stock.
Reviewed by automated data checks against the source filing. How we make and check alerts
Roy Baynes bought 1,646 shares of Natera, Inc. ($NTRA) on June 26, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $NTRA is up 8.4% after 1 week, down 1.5% after 1 month and up 50.2% to date (from the $261.91 close on Jun 26, 2026).
NTRA
Natera, Inc.
Key Points
- On June 26, 2026, Roy Baynes bought 1,646 shares of Natera, Inc. at a price of $277.79 per share, reflecting a growing confidence among insiders.
- Natera, Inc. has seen recent insider activity, with Rowan Chapman, Thomas Lynch Jr., and Roelof Botha also purchasing shares on the same day.
- Analysts maintain a strong buy recommendation for Natera, with a mean price target of $348.02, suggesting a positive outlook for the company's future.
Get $NTRA trade alerts by text
We text you when insiders, Congress or big funds trade $NTRA. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Natera, Inc. alert may contain errors. Disclosures
Insider Buying and Selling at Natera, Inc.
On June 26, 2026, Roy Baynes purchased 1,646 shares of Natera, Inc. (NTRA) on the NasdaqGS. The shares were bought at a price of $277.79 each. This transaction is part of a notable trend, as multiple insiders made purchases on the same day, indicating strong interest in the company's stock.
A Surge in Insider Activity
Baynes' acquisition adds to a wave of insider buying at Natera. On the same day, Rowan Chapman bought 1,674 shares, Thomas Lynch Jr. acquired 1,905 shares, and Roelof Botha purchased 1,691 shares. Each of these transactions reflects a collective confidence among executives in the company's future performance.
Analysts Set New Price Targets
Analysts remain optimistic about Natera, maintaining a consensus rating of strong buy. Recent reports show that firms like JP Morgan, Morgan Stanley, and TD Cowen have set price targets ranging from $435 to $480. These targets suggest that analysts believe the stock has significant growth potential.
What Natera, Inc. Does
Natera, Inc. is a diagnostics company that specializes in molecular testing services. It offers a range of tests, including those for cancer detection and genetic screening. The company's innovative solutions are critical in the healthcare sector, and the recent insider buying may signal a strong belief in its ongoing growth.
What to Watch at Natera, Inc.
Natera's next earnings report is scheduled for November 5, 2026. As the company approaches this date, investors will be keen to see how these insider transactions and analyst ratings play out. It's important to note that the insider transactions reported here reflect positions as of June 26, 2026, and may not represent current holdings.
Related Filing Alerts
Source: Roy Baynes's Form 4 filing on $NTRA (Jun 26, 2026). Find the original filing: NTRA Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts